Menu

David Peinsipp

Partner

I help disruptive technology companies grow and thrive, whether it is taking them public, helping them raise funds or partnering them with other companies.

dpeinsipp@cooley.com

full contact info

David is co-chair of Cooley's global capital markets practice group. David has a general business and corporate law practice, representing both emerging and public companies in a variety of matters, including capital markets transactions, Securities and Exchange Commission (SEC) reporting and compliance and corporate governance matters. He routinely represents issuers and investment banks in complex securities offerings, including IPOs, follow-on offerings, 144A offerings, PIPEs and direct listings. His practice also includes company formations, venture financings and general corporate matters.

Download full bio 

Experience

  • Global Blood Therapeutics – $345 Million Convertible Senior Notes Offering 

  • Sweetgreen – $418.6 Million IPO 

  • Lulu’s – $92 Million IPO 

  • NerdWallet – $150.1 Million IPO 

  • Thrasio Raises More Than $1 Billion With Series D Round 

  • View all

Practices & Industries
Passions

    IPOs

    Literature

    Gator football

Education

  • New York University School of Law
    JD, 2001

  • University of Florida
    BS, Psychology
    1998

Admissions & Credentials

California

Media & Insight
Memberships

  • American Bar Association

  • The Bar Association of San Francisco

Rankings & Accolades

    Daily Journal: California Lawyer Attorneys of the Year Awards (2020); Top 100 Lawyers in California (2019 – 2020); Top 20 Under 40 (2014)

    Chambers USA: Capital Markets: Debt & Equity – California & Nationwide (Western United States) (2019 – 2021)

    IFLR1000 US: Lawyer of the Year – Capital Markets (2020)

    Law 360: Capital Markets MVP (2019)

    Legal 500: Leading Lawyer - Capital Markets: Equity Offerings (2020 – 2021); Next Generation Lawyer - Capital Markets: Equity (2019)

Representative issuers:

Dave has represented companies/investment banks on capital market transactions involving issuers across industries, such as: 10X Genomics, Accelerate Diagnostics, Acutus Medical, Aerohive Networks, Alteryx, ALX Oncology, Ambarella, Applied Molecular Transport, Anthera Pharmaceuticals, Apigee, Applied Molecular Transport, Annexon, Apptio, Arcadia Biosciences, Arcutis Biotherapeutics, Aridis Pharmaceuticals, ARMO BioSciences, Ascendis Pharma, ASLAN Pharmaceuticals, Atlassian, Audentes Therapeutics, Cision, Crinetics Pharmaceuticals, Dermira, DocuSign, EHang, Eidos Therapeutics, Fantex, FireEye, Five Prime Therapeutics, Global Blood Therapeutics, Gossamer Bio, Gritstone Oncology, Guardant Health, Health Catalyst, HealthEquity, Hyperion Therapeutics, IGM Biosciences, Ignyta, Immune Design, Inhibrx, Invitae, Kodiak Sciences, LinkedIn, Livongo Health, MINDBODY, Mobile Iron, NantKwest, Nanthealth, New Relic, Ooma, Otonomy, Pliant Therapeutics, Principia Biopharma, ProNai, ProQR Therapeutics, PROS Holdings, Rigel Pharmaceuticals, Satsuma Pharmaceuticals, Savara, Shockwave Medical, Sierra Oncology, Snap, Stitch Fix, Sutro Biopharma, Syndax Pharmaceuticals, Tableau Software, Taiwan Liposome Company, Tricida, Trivascular, Uber, ViewRay, Xenon Pharmaceuticals, Yelp, Zendesk, Zscaler, Zymeworks, Zynga.

Contact

dpeinsipp@cooley.com

+1 415 693 2177